Table 3. Ongoing clinical trials evaluating decitabine drug in solid tumors.

Study number	Phase	Drug	Disease	Status completion date
NCT03875287	I	Decitabine Cedazuridine	Solid tumors	Recruiting August 2021
NCT04049344	II	Combination of decitabine with oxaliplatin	Relapsed/metastatic renal cell carcinoma	Recruiting December, 2021
NCT03445858	I	Pembrolizumab combined with Decitabine	Young adult patients with relapsed and refractory solid tumors or lymphoma	Recruiting January 12, 2025
NCT02959164	Ib	Decitabine and Gemcitabine	Refractory pancreatic adenocarcinoma and advanced soft tissue or bone sarcomas	Active, June, 2021 not recruiting